Sign in
CompletedEarly phase 1

Neuroendocrine Risk for PTSD in Women

Key facts

Who runs it
Emory University
Where
Atlanta, United StatesSee the site
Trial code
Status
Completed
Phase
Early phase 1
People taking part
127 people enrolled
Started
11 Nov 2019
Ended
30 Apr 2025
Type of study
Interventional, 12 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Estradiol patch
  • Placebo patch
Record updated
22 July 2026

Who can take part

Age
18 years to 35 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • African American women
  • A menstrual period within the past 60 days
  • Able and willing to give informed consent
  • Must have a smart phone and willing to install the Clue app

Who cannot take part

  • Women currently taking any form of hormone-based birth control or other hormonal supplement
  • Current psychoactive medication use
  • Weight >250lbs (a maximum weight to allow for participants to fit comfortably inside the bore of the MRI machine) and typical physical contraindications for MRI such as metal implants
  • Hypercoagulable conditions
  • History of embolism
  • Current symptoms of psychosis or bipolar disorder
  • History of major head injury or neurological disorder
  • Women who are pregnant or breastfeeding
  • Nicotine use or smoking

Where in United States

  • Grady Memorial HospitalAtlanta, United States

About the trial

What the trial wants to find out

This study will test for effects of estradiol (E2) on PTSD symptoms and functional magnetic resonance imaging (fMRI) indicators of stress vulnerability, in naturally-cycling women who are not using hormonal birth control. Enrollment will be targeted to create three groups within two cohorts (early follicular phase and luteal phase):

Read full original descriptionShow less

1. PTSD: Women who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for PTSD 2. Trauma-Exposed (TC): Women matched for age and trauma exposure severity but without PTSD 3. Healthy Control (HC): Women matched for age, but without trauma history or psychiatric disorder (self-reported)

Women will be recruited through Grady Trauma Project (GTP), a large longstanding study of civilian trauma and PTSD conducted at Grady Memorial Hospital in Atlanta, Georgia.

The 12 groups in the trial

  • Cohort 1: PTSD Receiving Estradiol then PlaceboTreatment being tested

    Participants with PTSD will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.

    Treatment: Estradiol patch and Placebo patch

  • Cohort 1: PTSD Receiving Placebo then EstradiolTreatment being tested

    Participants with PTSD will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.

    Treatment: Estradiol patch and Placebo patch

  • Cohort 1: Trauma without PTSD Receiving Estradiol then PlaceboExisting treatment, for comparison

    Participants with trauma exposure will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.

    Treatment: Estradiol patch and Placebo patch

  • Cohort 1: Trauma without PTSD Receiving Placebo then EstradiolExisting treatment, for comparison

    Participants with trauma exposure will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.

    Treatment: Estradiol patch and Placebo patch

  • Cohort 1: Healthy Controls Receiving Estradiol then PlaceboExisting treatment, for comparison

    Participants without trauma history or psychiatric disorder will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.

    Treatment: Estradiol patch and Placebo patch

  • Cohort 1: Healthy Controls Receiving Placebo then EstradiolExisting treatment, for comparison

    Participants without trauma history or psychiatric disorder will will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.

    Treatment: Estradiol patch and Placebo patch

  • Cohort 2: PTSD Receiving Estradiol then PlaceboTreatment being tested

    Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.

    Treatment: Estradiol patch and Placebo patch

  • Cohort 2: PTSD Receiving Placebo then EstradiolTreatment being tested

    Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.

    Treatment: Estradiol patch and Placebo patch

  • Cohort 2: Trauma Control Receiving Estradiol, then PlaceboExisting treatment, for comparison

    Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.

    Treatment: Estradiol patch and Placebo patch

  • Cohort 2: Trauma Control Receiving Placebo then EstradiolExisting treatment, for comparison

    Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.

    Treatment: Estradiol patch and Placebo patch

  • Cohort 2: Healthy Control Receiving Estradiol then PlaceboExisting treatment, for comparison

    Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.

    Treatment: Estradiol patch and Placebo patch

  • Cohort 2: Healthy Control Receiving Placebo then EstradiolExisting treatment, for comparison

    Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.

    Treatment: Estradiol patch and Placebo patch

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The LOW E2 STUDY- Neuroendocrine Risk Mechanisms for Post-traumatic Stress Disorder in Women
Record updated
22 July 2026